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Cryptococcus neoformans Dual GDP-Mannose Transporters and Their
Role in Biology and Virulence
Zhuo A. Wang,a Cara L. Grifﬁth,a* Michael L. Skowyra,a* Nichole Salinas,a Matthew Williams,a Ezekiel J. Maier,c,d Stacey R. Gish,a
Hong Liu,a* Michael R. Brent,b,c,d Tamara L. Doeringa
Departments of Molecular Microbiologya and Geneticsb and The Center for Genome Sciences,c Washington University School of Medicine, St. Louis, Missouri, USA;
Department of Computer Science, Washington University, St. Louis, Missouri, USAd
Cryptococcus neoformans is an opportunistic yeast responsible for lethal meningoencephalitis in humans. This pathogen elabo-
rates a polysaccharide capsule, which is its major virulence factor. Mannose constitutes over one-half of the capsule mass and is
also extensively utilized in cell wall synthesis and in glycosylation of proteins and lipids. The activated mannose donor for most
biosynthetic reactions, GDP-mannose, is made in the cytosol, although it is primarily consumed in secretory organelles. This
compartmentalization necessitates specific transmembrane transporters to make the donor available for glycan synthesis. We
previously identified two cryptococcal GDP-mannose transporters, Gmt1 and Gmt2. Biochemical studies of each protein ex-
pressed in Saccharomyces cerevisiae showed that both are functional, with similar kinetics and substrate specificities in vitro. We
have now examined these proteins in vivo and demonstrate that cells lacking Gmt1 show significant phenotypic differences from
those lacking Gmt2 in terms of growth, colony morphology, protein glycosylation, and capsule phenotypes. Some of these obser-
vations may be explained by differential expression of the two genes, but others suggest that the two proteins play overlapping
but nonidentical roles in cryptococcal biology. Furthermore, gmt1 gmt2 double mutant cells, which are unexpectedly viable,
exhibit severe defects in capsule synthesis and protein glycosylation and are avirulent in mouse models of cryptococcosis.
Mannose is a dominant component of fungal glycoconjugates,in contrast to its lesser role in parallel structures of higher
organisms. For example, in both mammals and fungi N-glycosy-
lation of proteins begins with the transfer to asparagine of a con-
served structure consisting of twoN-acetylglucosamine and eight
mannose residues in the endoplasmic reticulum. Mammals typi-
cally process this initial structure to forms with only three man-
nose residues, elaborating the modified core with other moieties
such as galactose, N-acetylglucosamine, and N-acetylneuraminic
acid in the Golgi apparatus (1). In contrast, yeasts maintain most
or all of the initial mannose-rich structure and frequently elabo-
rate it to various extents with additional mannose residues, rang-
ing from the relatively limited elongation seen inC. neoformans to
the extensive modifications observed in Saccharomyces cerevisiae
(2, 3). As another example, mammalian O-glycans typically con-
tain fucose, xylose, andN-acetylglucosamine (1). In contrast, fun-
gal O-glycans are initiated by the addition of mannose to serine/
threonine residues and are generally elongated with several more
mannoses (2, 4). Proteins extensively modified with mannose
(mannoproteins) are important constituents of fungal cell walls,
so that mannose constitutes 30 to 50% of the cell wall mass of the
model yeast S. cerevisiae (5). Mannose further occurs as a compo-
nent of fungal glycolipids (2), GPI anchors (6), and capsules (see
below).
Glycan biosynthetic reactions require high-energy monosac-
charide donors; in the case of mannose, this compound is the
nucleotide sugar GDP-mannose. Its synthesis is catalyzed by the
action of GDP-mannose phosphorylase on GTP and mannose-1-
phosphate; the latter is generated in the cytosol from mannose-
6-P (7). Some GDP-mannose is used at the cytosolic face of the
endoplasmic reticulum (ER) to form lipid-linked oligosaccharide
precursors of N-glycans (7) or dolichol-P-mannose. These prod-
ucts are subsequently flipped into the ER for further modification
or for use as mannose donors in glycosylation reactions, respec-
tively (8). Most GDP-mannose, however, is used as a substrate for
glycosylation reactions in the lumen of the Golgi complex (7). To
enter the Golgi, this negatively charged compound requires a spe-
cific nucleotide sugar transporter (9, 10). GDP-mannose trans-
port activity was first identified and characterized through in vitro
studies of S. cerevisiae (11). VRG4, the gene encoding the GDP-
mannose transporter, was subsequently identified in S. cerevisiae
(12, 13) and other fungi (see below). GDP-mannose transporters
have also been reported in plants (14–16) and the protozoan par-
asiteLeishmania donovani (17, 18).Notably,mammalian cells lack
GDP-mannose transporters, since they do not performmannosy-
lation in the Golgi.
As expected from its role in GDP-mannose transport, the S.
cerevisiae Vrg4 protein is localized to the Golgi apparatus and
required for normal Golgi functions (12, 13); the corresponding
VRG4 gene is essential (12). Viable cells that express partly func-
tional mutant Vrg4 have been reported, but these strains show
defects in both N- and O-linked protein glycosylation and are
more sensitive than their wild-type counterparts to cell wall stress
(12, 13, 19). Single VRG4 homologs have been identified in mul-
tiple fungi, including Pichia pastoris (20), Aspergillus niger (21),
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Aspergillus fumigatus (22), Candida glabrata (23), and Candida
albicans (24); all of them complement S. cerevisiae vrg4 mutants.
While most of these genes, like the S. cerevisiae VRG4 gene, are
essential, it is notable that A. fumigatus cells lacking GmtA are
viable although significantly impaired (22). The GDP-mannose
transporter of the protozoan parasite L. donovani is also not es-
sential for cell viability, although it is required for parasite viru-
lence (17, 18). Finally, the Aspergillus nidulans genome contains
two VRG4-like genes, gmtA and gmtB (25). Both of these are
thought to encode functional GDP-mannose transporters since
the reduced cell surface mannosylation of a gmtA mutant can be
corrected by overexpression of gmtB (26); a double mutant has
not been reported.
Our studies focus on the encapsulated fungal pathogen Cryp-
tococcus neoformans, which causes severe disease in immunocom-
promised individuals and over 600,000 deaths per year worldwide
(27). Pathogenic members of the Cryptococcus genus have histor-
ically been classified by seroreactivity of their capsule polysaccha-
rides (28); serotypes A and D are the main ones responsible for
opportunistic infections. The glycoconjugates of C. neoformans
include mannose-containing glycoproteins and glycolipids (3, 4,
29, 30). Mannose is also a major component of this organism’s
extensive polysaccharide capsule (31), which is essential for fungal
virulence. The capsule is composed primarily of two polysaccha-
rides, glucuronoxylomannan (GXM) and glucuronoxyloman-
nogalactan (GXMGal; also termed GalXM [28]), along with a
small amount of mannoproteins (31). GXM accounts for about
90% of the capsule mass and consists of a mannose backbone
modified with xylose, glucuronic acid, and acetyl groups (32).
Mutants lacking GXM are avirulent in animal models, suggesting
that it plays an important role in pathogenesis (33). We have re-
ported that GXM is made within the secretory pathway (34),
which would require the translocation of GDP-mannose into lu-
minal compartments. The second capsule polymer, GXMGal, is
less well understood but is also associated with cryptococcal viru-
lence (35). GXMGal is based on a linear polymer of galactose, and
its side chains contain mannose residues along with galactose,
glucuronic acid, and xylose (36–38).
We previously identified two C. neoformans genes encoding
GDP-mannose transporters, GMT1 and GMT2, which encode
proteins that are 63% identical at the amino acid level (39). Each
of these genes effectively complements the S. cerevisiae vrg4 mu-
tant, and the two proteins demonstrate similar GDP-mannose
transport activity in vitro (39). Strains lacking either gene are via-
ble, although the mutants do have distinct phenotypes, with gmt1
cells exhibiting a severe capsule defect while gmt2 cells produce
normal capsules (39). In addition, transcriptional analysis sug-
gests that the two genes are not coordinately regulated and there-
fore may have distinct biological functions in C. neoformans (39).
To investigate potential functional differences between the two
cryptococcal GDP-mannose transporters, we generated a double
mutant strain and evaluated mannose-related phenotypes of the
single and double mutants in comparison to the parental strain.
We also assessed phenotypes and GMT transcription in strains in
which the coding sequence of each gene was expressed from the
usual chromosomal location of the other. Finally, we determined
that loss of both transporters has significant impact on capsule
synthesis and protein glycosylation and completely abrogates fun-
gal virulence.
MATERIALS AND METHODS
Cell growth.AllC. neoformans strains (Table 1) were grown at 30°C if not
otherwise indicated. Cells were cultured in YPD medium (1% [wt/vol]
yeast extract, 2% [wt/vol] peptone, 2% [wt/vol] dextrose) with shaking
(230 rpm) or grown on YPD agar plates (YPD medium with 2% [wt/vol]
agar); for strains marked with drug resistance cassettes, 100 g/ml
nourseothricin (Werner BioAgents) or Geneticin (G418; Invitrogen)
and/or 150 g/ml hygromycin B (Roche) was included in the medium.
For immunofluorescence localization, strains were cultured in minimal
medium, consisting of 0.17%yeast nitrogen basewithout amino acids and
(NH4)2SO4, 0.5% (wt/vol) (NH4)2SO4, and 2% (wt/vol) dextrose. To test
C. neoformans growth in the presence of stressors, cells from an overnight
culture were washed, resuspended in water at an optical density at 600 nm
(OD600)/ml of 1, and diluted 10-fold with YPD medium containing caf-
feine, sodium dodecyl sulfate (SDS), or hygromycin B to yield the desired
concentrations. Aliquots of 100 l of these suspensions were transferred
into a 96-well plate and incubated to follow growth by OD600.
Strain construction (serotype D). To make a gmt1 gmt2 double mu-
tant, the gmt2 deletion construct described previously (39) was biolisti-
cally transformed into a gmt1 mutant strain (39). Genomic DNA was
extracted fromdrug-resistant transformants and screened by PCR to con-
firm replacement ofGMT2 by the appropriatemarker. DNAblotting (not
shown) confirmed the presence of both gene replacements and the ab-
sence of additional ectopic insertions of drug markers.
For Gmt2 localization, the coding sequence of the serotype D gene,
designated hereGMT2(D), was PCR amplified from JEC21 genomicDNA
(4) using primersGMT2-1 andGMT2-2 to generate a 2,914-bpGMT2(D)
DNA fragment, GMT2-3 and GMT2-4 to generate a DNA fragment con-
sisting of the 26-bp FLAG epitope and 336 bp 3= to the GMT2 gene, and
GMT2-7 and GMT2-8 to generate a 1,142-bp GMT2(D) downstream
DNA fragment. A 2,821-bp hygromycin resistance cassette was amplified
fromplasmid pHYG7-KB1 (40) using primersGMT2-5 andGMT2-6. The
four amplicons were next assembled by fusion PCR and cloned into the
pCR2.1-TOPOvector (Invitrogen) to form the plasmid pGMT2(D)-Flag-
Hyg. To improve transformation efficiency, the hygromycin resistance
cassette of pGMT2(D)-Flag-Hyg was replaced by a cassette encoding Ge-
neticin resistance inserted in the opposite orientation from the GMT2
gene. To do this, the latter cassette was released from pIB103 (41) by
digestion with BlpI and AgeI and cloned into BlpI- and AgeI-digested and
calf intestinal alkaline phosphatase-treated pGMT2(D)-Flag-Hyg to form
the plasmid pGMT2(D)-Flag-G418. To prepare DNA for transformation
using a split marker disruption strategy (42), a fragment of DNA contain-
ing the GMT2-Flag sequence and the 3= portion of the Geneticin resis-
TABLE 1 C. neoformans strains used in these studies
C. neoformans straina Serotype Origin
KN99 A 61
KN99 gmt1 A This study
KN99 gmt2 A This study
KN99 gmt1 gmt2 A This study
KN99 gmt1::GMT1 A This study
JEC21 D 62
JEC21 gmt1 D 39
JEC21 gmt2 D 39
JEC21 gmt1::GMT1 D 39
JEC21 gmt1 gmt2 D This study
JEC21 gmt1 gmt2::GMT1b D This study
JEC21 gmt2 gmt1::GMT2b D This study
JEC21 GMT1-HA D 4
JEC21 GMT1-HA GMT2-FLAG D This study
a All strains are MAT.
b In these strains, only the coding region was moved to a new location; flanking regions
retained the native sequences.
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tance cassette was released from pGMT2(D)-Flag-G418 by digestion
with ClaI and SmlI. An overlapping fragment consisting of GMT2(D)
downstream sequence and the 5= portion of the Geneticin resistance
cassette was released from the same plasmid by digestion with PstI and
KpnI. To replace the chromosomal copy of the GMT2 gene with
GMT2-Flag, the two overlapping DNA fragments were mixed at an
equimolar ratio and biolistically transformed into a strain expressing
Gmt1-HA (4). Genomic DNA was prepared from Geneticin-resistant
transformants and screened by PCR. Gmt2-Flag protein expression
was confirmed by immunostaining.
We wanted to generate strains in which only one GMT gene was ex-
pressed and that gene was expressed from the opposite locus. To express
the coding sequence of GMT1 from the GMT2 locus, maintaining the
GMT2 promoter and terminator, we again used fusion PCR and a split
marker strategy to modify the gmt1 strain. We first used JEC21 genomic
DNA as a template to amplify a 1,776-bp fragment consisting of the
GMT1(D) coding sequencewith 3=-terminal addition of a 20-bp fragment
of the GMT2(D) downstream sequence using primers ZAW-117 and
ZAW-118; a 910-bp fragment of sequence upstream of GMT2(D) using
primers ZAW-115 and ZAW-116; and a 937-bp fragment of sequence
downstream of GMT2(D) using primers ZAW-119 and ZAW-120. We
also amplified an 867-bp portion of a nourseothricin resistance cassette
with 5=-terminal addition of a 20-bp fragment of the GMT2(D) down-
stream sequence from plasmid pGMC200 (43) using primers ZAW-114
andZAW-078; an overlapping 1,392-bp fragment of the same cassette was
amplified using primersGMT1CB-E andGMT1CB-F. The 1,776-bp, 910-
bp, and 851-bp amplicons were next assembled by fusion PCR and cloned
into the pCR2.1-TOPO vector (Invitrogen) to form the plasmid
pGMT1R2-5; this construct was confirmed by DNA sequencing. The
937-bp and 1,392-bp amplicons were similarly assembled, and the prod-
uct was mixed at a 1:1 molar ratio with the fragment released by XbaI and
SpeI digestion of plasmid pGMT1R2-5. The mixed DNA was biolistically
transformed into the serotype D gmt1 strain as described above. Trans-
formants were identified by nourseothricin resistance and verified by PCR
analysis and DNA sequencing (not shown).
To express the coding sequence ofGMT2 from theGMT1 locus,main-
taining the GMT1 promoter and terminator, we used overlap PCR and a
split marker strategy to modify the gmt2 strain. We used JEC21 genomic
DNA as the template to generate a 1,613-bp fragment consisting of the
GMT2(D) coding sequencewith 3=-terminal addition of a 21-bp fragment
of the GMT1(D) downstream sequence using primers ZAW-128 and
ZAW-129, an 820-bp fragment of sequence upstream of GMT1(D) using
primers ZAW-126 and ZAW-127, and an 841-bp fragment of sequence
downstream ofGMT1(D) using ZAW-134 and ZAW-135.We also ampli-
fied a 1,725-bp segment of a Geneticin resistance cassette from plasmid
pIB103 (44) with 5=-terminal addition of a 21-bp fragment of GMT1(D)
downstream sequence using primers ZAW-130 and ZAW-131 and an
overlapping 1,554-bp fragment using primers ZAW-132 and ZAW-133.
The 1613-bp, 820-bp, and 1,725-bp amplicons were next assembled by
fusion PCR and cloned into the pCR2.1-TOPO vector (Invitrogen) to
form plasmid pGMT2R1-5; this construct was checked by DNA sequenc-
ing. The 841-bp and 1,554-bp amplicons were similarly assembled, and
the product was mixed at a 1:1 molar ratio with the fragment released
from the plasmid pGMT2R1-5 by digestion with XbaI and SpeI. The
mixed DNA was biolistically transformed into the serotype D gmt2 strain
as described above. Transformants were identified byGeneticin resistance
and verified by PCR analysis and DNA sequencing (not shown).
Virulence studies (serotype A). For use in mouse infections, mutant
strains were generated in the more virulent serotype A background. For
gmt1, a 1,248-bp fragment upstream of the serotype A gene, designated
here GMT1(A), was amplified from KN99 genomic DNA using primers
Gmt1-7 andGmt1-4b, and a 1,329-bp fragment downstreamofGMT1(A)
was amplified using primers Gmt1-5b andGmt1-8. A 2,930-bp hygromy-
cin resistance cassette was amplified from plasmid pHYG7-KB1 using
primers Gmt1-3b and Gmt1-6. The three amplicons were next assembled
by fusion PCR, and the final construct was biolistically transformed into
KN99 cells. For gmt2, a 1,295-bp fragment upstream of the serotype A
gene, designated here GMT2(A), was amplified from KN99 genomic
DNAusing primers Gmt2-7 andGmt2-4, and a 1,294-bp fragment down-
streamofGMT2(A)was amplified using primersGmt2-5b andGmt2-8. A
1,868-bp nourseothricin resistance cassette was amplified from plasmid
pGMC200 using primers Gmt2-3 and Gmt2-6. The three amplicons were
next assembled by fusion PCR, and the final construct was biolistically
transformed into KN99 cells. Transformed cells were allowed to recover
for 24 h on YPDmedium, transferred onto YPD plates containing hygro-
mycin or nourseothricin as appropriate, and incubated at 30°C for 3 to 5
days. For the gmt1 gmt2 double mutant, the gmt2 deletion construct de-
scribed above was biolistically transformed into the serotype A gmt1mu-
tant strain. For all strains, genomic DNA was extracted from drug-resis-
tant transformants and screened by PCR to confirm replacement of
GMT1(A) or GMT2(A) by the appropriate markers. DNA blotting was
used to confirm gene replacements and that anymarker cassette was pres-
ent only once in the genome, with no additional ectopic insertions.
To complement the serotype A gmt1 strain at the original locus using
overlap PCR and a split marker strategy, a 2,819-bp GMT1(A) sequence
with its flanking sequences was PCR amplified from KN99 genomic
DNA using primers GMT1CB-A and GMT1CB-B; a 985-bp fragment of
sequence downstream of GMT1(A) was amplified from the same DNA
usingGMT1CB-G andGMT1CB-H. An 851-bp portion of a nourseothri-
cin resistance cassette was amplified from plasmid pGMC200 using prim-
ers GMT1CB-C and GMT1CB-D; an overlapping 1,392-bp fragment of
the same cassette was amplified using primers GMT1CB-E and
GMT1CB-F. The 2,891-bp and 851-bp amplicons were next assembled by
fusion PCR and cloned into the pCR2.1-TOPO vector (Invitrogen) to
form the plasmid pGMT1CB-5. The 985-bp and 1,392-bp ampliconswere
similarly assembled and cloned to form the plasmid pGMT1CB-3. The
two fused fragments were released from their respective vectors by diges-
tion with XbaI and SpeI, mixed at a 1:1 molar ratio, and biolistically
transformed into the disruption strain as described above. Transformants
were identified by nourseothricin resistance, and complementation was
verified by PCR analysis and reversion of phenotypes (not shown).
Strains to be testedwere cultured overnight in YPDmedium, collected
by centrifugation, washed in phosphate-buffered saline (PBS), and di-
luted to 2  106 cells/ml in PBS. For each strain, 10 4- to 6-week-old
female A/Jcr mice (from the National Cancer Institute) were anesthetized
with a combination of ketamine hydrochloride (Ketaset) and xylazine and
inoculated intranasally with 100 l of the prepared suspenstion of C.
neoformans. The animals were weighed the day of inoculation and were
sacrificed if weight decreased to a value below 80% of peak weight on any
subsequent day (an outcome which in this protocol precedes any signs of
disease) or upon completion of the study. Initial inocula were plated to
confirmCFU.All studieswere performed in compliancewith institutional
guidelines for animal experimentation.
Immunoblotting. Cells from a 3-ml overnight culture in YPD me-
dium were harvested by centrifugation (2,500  g, 10 min, 4°C) and
washed in 500 l of cold lysis buffer (50 mM Tris-HCl, pH 8.0, 0.1 mM
EDTA, and 1% SDS) with protease inhibitors (chymostatin, leupeptin,
antipain, and pepstatin A, each at 10 g/ml final concentration, and 0.2
mMphenylmethylsulfonyl fluoride). The suspension was then vigorously
vortex mixed with 200 l of 0.5-mm glass beads (Biospec Products,
Bartlesville, OK) for 1-min intervals alternating with 2 min on ice until
80% breakage was observed under a light microscope. The lysate was
centrifuged (6,000 g, 1 min, at room temperature [RT]), and the super-
natant was reserved. Protein concentration of each sample was deter-
mined by Bio-Rad protein assay (Bio-Rad). Equal amounts of protein
from each fraction were boiled in SDS-PAGE sample buffer and resolved
by SDS-PAGE on a 12% gel. Standardmethods were used for transfer and
immunoblotting, using dilutions of 1:1,000 for rabbit polyclonal anti--
1,6-mannose antibody (45) and rabbit polyclonal anti-cell wall protein
antibody (CWP) (46), and 1:5,000 for chicken polyclonal anti--elimi-
Wang et al.
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nated mannoprotein antibody (from S. Levitz, Boston University School
of Medicine, Boston, MA) and secondary antibodies (anti-chicken IgG
conjugated to horseradish peroxidase from Sigma; anti-rabbit IgG conju-
gated to horseradish peroxidase fromGEHealthcare). Detection was with
the Western Lighting chemiluminescence reagent (PerkinElmer Life Sci-
ences).
Capsule induction. For capsule induction, single colonies were inoc-
ulated into 50ml of YPDmedium and shaken overnight at 30°C. Approx-
imately 108 cells were collected by centrifugation (2,500 g, 10min, 4°C),
washed twice with 1 ml Dulbecco’s modified Eagle medium (DMEM;
Sigma), and resuspended in DMEM at 106/ml. The washed cell suspen-
sion was then transferred into a 24-well tissue culture plate (TPP; 1 ml/
well) and incubated at 37°C in a 5% CO2 atmosphere. After 48 h, the cells
were collected by centrifugation, resuspended in 8l PBS, andmixedwith
1.5 l India ink. A 5-l volume of the suspension was spotted onto a
microscope slide, and cells were viewed with a ZEISS Axioskop2 MOT
Plus microscope (Carl Zeiss, Thornwood, NJ) with a 40 objective. Ran-
dom fields were photographed and printed for manual measurement of
capsule radius and cell diameter.
RNA-Seq.Wild-type cells were cultured overnight in YPD followed by
growth in capsule-inducing conditions (DMEM, 37°C, 5% CO2), RNA
isolation, and transcriptome sequencing (RNA-Seq) analysis as described
in reference 47. RNA was isolated at 0, 1.5, 3, 8, and 24 h of culture.
qRT-PCR. For quantitative reverse transcriptase PCR (qRT-PCR),
cells were cultured overnight in YPD and then either harvested directly or
grown under capsule-inducing conditions as above for 3 h. RNA was
prepared from108 cells and analyzed as described in reference 39 using the
following primers: ZAW-117 and ZAW-166 for GMT1; ZAW-063 and
ZAW-137 for GMT2; and ZAW-171 and ZAW-172 for ACT1 (for nor-
malization).
Microscopy. Capsule immunofluorescence was performed as de-
scribed in reference 39 using 50 g/ml anti-capsular monoclonal anti-
body 3C2 (from T. Kozel, University of Nevada at Reno) followed by 200
ng/ml of Alexa Fluor 488-tagged anti-mouse antibody (Invitrogen).
Transmission electron microscopy was performed exactly as described in
reference 48.
For protein localization, sample preparation formicroscopy was done
as described in reference 4. After blocking, slides were treated with either
a high-affinity rat anti-hemagglutinin (anti-HA) monoclonal antibody
(Roche Applied Science; 20 ng/ml in blocking buffer) together with a
mouse anti-FLAG monoclonal antibody (Sigma; 80 ng/ml in blocking
buffer) or blocking buffer alone. Secondary antibody treatment was with
Alexa Fluor 594-tagged goat anti-rat IgG and Alexa Fluor 488-tagged goat
anti-mouse IgG (Invitrogen; 1 g/ml in blocking buffer) as appropriate.
RESULTS
In our earlier studies of GDP-mannose transport in C. neofor-
mans, we deleted the genes encodingGmt1 andGmt2 in a serotype
D strain background (39). The resulting gmt1 and gmt2 single
mutants grew like the wild type in rich medium at both 30°C and
37°C (reference 39 and data not shown), although gmt1 cells
showed a modest growth defect at 37°C in the presence of the cell
wall stressor calcofluorwhite (Fig. 1). To further define the roles of
the two cryptococcal transporters in the biology of this fungal
pathogen, we generated a double mutant strain in the same back-
ground. The double mutant showed only mildly reduced viability
at 30°C (Fig. 1). This was surprising, given the essentiality of
VRG4, the gene encoding the single GDP-mannose transporter in
S. cerevisiae (12) (see Discussion). The double mutant was not
viable at 37°C, however, either in the presence of 80 g/ml calco-
fluor white (Fig. 1) or its absence (not shown).
GDP-mannose transport is important in fungi for the synthesis
of cell wall polysaccharides (22) and mannoproteins (24), so de-
fects in this process generally correlate with defects in cell wall
integrity (12). To test this property in our strains, we examined the
growth of gmtmutants at 30°C in the presence of SDS concentra-
tions ranging from 0.0001% to 0.1% (Fig. 2). The single mutants
responded likewild-type cells to this stressor. In contrast, the gmt1
gmt2 double mutant was significantly more sensitive, showing
only half as much growth as the other strains at 0.0025% SDS, a
concentration at which the wild type and single mutants grew
normally. The double mutant was also more sensitive to caffeine,
sorbitol, ruthenium red, and hygromycin B (data not shown).
(Addition of sorbitol to provide osmotic support did not reduce
sensitivity to the other stressors [data not shown].) In all of these
conditions, each single mutant behaved like the wild type.
Based on the growth defects of the double mutant, we sus-
pected that it might have reduced virulence in a mouse model of
cryptococcal infection. To test this, we generated gmt1 and gmt2
single and double mutants in the more virulent serotype A back-
ground (see Materials and Methods). As suspected, the double
mutant was completely avirulent, although single mutants had
normal virulence (Fig. 3 and data not shown).
Our results to this point suggested that Gmt1 and Gmt2 are
redundant proteins involved in a key cellular process. Each pro-
tein can presumably compensate for loss of the other, but in the
FIG 1 Temperature sensitivity of gmtmutants. Aliquots of 5 l of a stock cell
suspension (OD600  0.1) and three 5-fold serial dilutions were spotted on
YPD plates containing 80 g/ml calcofluor white and grown for 5 days at the
temperatures shown. Strains used in all figures are in the serotype D JEC21
background unless indicated otherwise. WT, wild type.
FIG 2 Mutants lacking both GMT1 and GMT2 are sensitive to cell stress.
Growth at 24 h, measured as fold increase compared to the starting culture, is
plotted as a function of SDS concentration in themedium. The doublemutant
(filled circles) is highly sensitive to SDS compared to wild-type and single
mutant strains.
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double mutant function is so compromised that it alters critical
phenotypes. This model is consistent with our in vitro studies that
showed similar activities of the two proteins when each was ex-
pressed individually in S. cerevisiae (39) and suggests that they
have the same cellular function. One observation, however, led us
to question this model: we had noted a growth defect in gmt1 cells
at 37°C in the presence of 80 g/ml calcofluor white (Fig. 1) that
was not evident in gmt2. To probe potential specific functions of
the two transporters, we therefore explored additional pheno-
types.
Beyond its occurrence in capsule and cell wall, mannose is a
major component of both N- andO-linked glycans in yeast (2–4).
We broadly surveyed protein N-glycosylation in gmt mutants by
performing immunoblotting experiments with an antibody spe-
cific for terminal 1,6-mannose, which is added to N-glycans in
the Golgi complex (2). The gmt1 gmt2 double mutant showed a
striking defect in this modification; similar results were observed
whenweused antiserummade against beta-eliminated cryptococ-
cal mannoproteins (lacking O-glycans) (Fig. 4A).We also noted a
modest but consistent effect on protein glycosylation in the ab-
sence of GMT1; several polypeptides demonstrated increased gel
migration, consistent with reduced glycosylation, and the overall
signal was slightly reduced compared to that of the wild type (Fig.
4B). We obtained qualitatively similar results when we probed
blots with antiserummade against an S. cerevisiae cell wall protein
(46) that cross-reacts with several cryptococcal polypeptides (data
not shown). Notably, the absence of GMT2 did not significantly
change the glycosylation profile from that of the wild type in par-
allel studies with each antibody (data not shown). These results
suggested that while both Gmt proteins act in protein glycosyla-
tion, Gmt1 plays a more important role.
We found evidence for a dominant role for Gmt1 in several
contexts beyond protein glycosylation. In the course of our
growth studies, we had noticed that gmt1 gmt2 double mutant
cells tended to form clumps in liquid medium. We observed a
mild version of this phenotype in cultures of gmt1, although not in
cultures of gmt2 (Fig. 5, top panel).We also noticed a difference in
colony morphology (Fig. 5, bottom panel); the gmt1 mutant col-
ony surface was duller than that of the wild type, while the gmt2
mutant showed no obvious defect. Both cell clumpiness and dull
colony morphology are suggestive of a defect in capsule produc-
tion, as in the acapsular cap67mutant shown for comparison (Fig.
5). The colonies of the double mutant not only were dull but also
showed a distinctly altered morphology (Fig. 5, bottom panel).
The cell wall defects of this strain that are suggested by its SDS
sensitivity (Fig. 2) may contribute to this phenotype.
Mannose is a major component of both of the cryptococcal
capsule polysaccharides (GXM and GXMGal [32, 36, 37]), and
FIG 3 The gmt1 gmt2 doublemutant is severely attenuated for virulence.Mice
were monitored for 50 days after inhalational inoculation with 2 105 cells of
the indicated serotype A strains. Animals exhibiting loss of greater than or
equal to 20% of body weight were humanely sacrificed.
FIG 4 Single gmt mutations have modest effects on protein glycosylation.
Total protein fractions of the strains indicated were resolved by SDS-PAGE
and immmunoblotted with antibody specific for terminal-1,6-mannose res-
idues or mannoproteins, as indicated below. Panel A, 10% gel; panel B, 12%
gel. *, examples of bands that migrate faster in gmt1 cells; the wild type was
loaded twice to facilitate comparison. For each panel, the same amount of
protein was loaded in all lanes.
FIG 5 Cells lacking Gmt proteins have altered morphology. (Top) The indi-
cated strains were grown in YPD, and the fraction of cells occurring as single
cells (open bars), in small aggregates (2 or 3 cells, gray bars), and clumps (3
cells, black bars) was determined. A representative experiment is shown,where
at least 200 cells of each strain were categorized. (Bottom) Photographs of
representative colonies of the indicated strains, grown on YPD. The light re-
flection seen on wild-type and gmt2 cells indicates normal encapsulation,
manifested as shiny colony morphology.
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earlier studies have shown that the absence of GDP-mannose syn-
thesis severely curtails capsule production (49). We previously
demonstrated that GXM is synthesized in the secretory pathway
(34), likely in the Golgi complex. Together, these findings imply
that capsule synthesis requires the transport of GDP-mannose
into the Golgi complex and therefore would need an appropriate
transporter. To probe the capsule defect suggested by the dull
colony and clumpy growth morphologies that we had observed,
we stained our panel of mutants with a monoclonal anticapsule
antibody. We noted that the gmt1 cells stained less intensely than
the wild-type and gmt2 strains, consistent with a partial capsule
defect (Fig. 6A and data not shown). Strikingly, the gmt1 gmt2
double mutant showed no detectable fluorescent signal, suggest-
ing a complete lack of GXM that is comparable to what is seen in
an acapsular mutant (Fig. 6A).
Under certain growth conditions, including those mimicking
aspects of the mammalian host environment, cryptococci gener-
ate significantly enlarged capsules (28). To assess the ability of the
gmt mutants to upregulate capsule production, we grew the cells
under capsule-inducing conditions. We then used negative stain-
ing with India ink to visualize the capsules and measured them to
quantitate induction (Fig. 6B). Consistent with the experiments
presented above, gmt1 mutant cells displayed significantly re-
duced capsule thickness compared to that of the wild type (1.5	
0.2 m versus 3.7	 0.1 m; P
 0.05); complementation of this
mutant with the wild-type GMT1 gene restored it to wild-type
thickness (3.6	 0.2m; P 0.4). Capsules of gmt2 cells were also
similar to those of wild-type cells (3.9	 0.1 m; P 0.2), while
the capsules of gmt1 gmt2 double mutant cells were undetectable,
even under these inducing conditions.
The thickness of the capsule, which reflects fiber length (50,
51), was clearly reduced in gmt1mutants, but these studies did not
address fiber density. To investigate this, we performed electron
microscopy (Fig. 6C). We noted that gmt1 fibers were markedly
more sparse than those of the wild type, although the comple-
mented gmt1mutant and gmt2 cells looked normal in this respect.
Consistentwith our observations by lightmicroscopy,we detected
no capsule fibers on the surfaces of gmt1 gmt2 doublemutant cells.
Our results suggested that in contrast to cell wall integrity phe-
notypes, where the two transporters seem to effectively compen-
sate for one another, normal growth at 37°C, protein N-glycosy-
lation, and capsule synthesis all relymore heavily on the activity of
Gmt1 and are dramatically impaired in the absence of both pro-
teins (see Discussion). Because of the similar in vitro activities of
these proteins (39), we suspected that the apparent difference in
protein function was due to levels of expression. We therefore
evaluated gene expression by RNA-Seq at various time points of
capsule induction. This study showed significantly higher expres-
sion ofGMT1, which ranged from roughly 3-fold that ofGMT2 in
rich medium (YPD, zero time in Fig. 7) to over 25-fold after 1 day
under capsule-inducing conditions (24 h in Fig. 7).
To confirm our hypothesis that the phenotypic differences be-
tween gmt1 and gmt2 reflected the distinct expression levels of
their remaining GMT genes, we performed a gene swap experi-
ment, diagrammed in Fig. 8 (panel A). To do this, we replaced the
wild-typeGMT gene that remained in each singlemutant with the
absent coding sequence. This generated pairs of strains expressing
the same gene fromdifferent genomic contexts (GMT2 in strains 2
and 5; GMT1 in strains 3 and 4). When we measured GMT gene
expression in these strains by qRT-PCR, we noticed that absence
of either GMT did not significantly alter expression of the other
(Fig. 8C; compare strains 2 and 3 to strain 1). This suggests that
there is no mechanism for compensatory upregulation of either
GMT upon loss of the other. We also noted that movement of
GMT1 from its native locus (strain 3) to theGMT2 locus (strain 4)
reduced its expression roughly 25-fold, consistent with the RNA-
Seq expression differences between these loci that we observed in
wild-type cells under the same inducing conditions (Fig. 7). The
change in GMT2 expression between the two sites, however, was
significantly less (roughly 3-fold; compare strains 2 and 5), al-
though in the expected direction.
We next assessed capsule induction by negative staining after
growth under inducing conditions.We found that movingGMT1
to the usual site of GMT2 caused reduced GMT1 expression and
dramatic reduction in capsule thickness (Fig. 8B and C; compare
strains 3 and 4). Furthermore, moving GMT2 to the usual site of
GMT1 caused an increase in gene expression and capsule size
(compare strains 2 and 5). These data are consistent with a model
of interchangeable transporters, which differ only in expression
FIG 6 Capsule alteration in gmtmutants. (A) Antibody staining. Bright-field
images of the indicated strains grown under capsule-inducing conditions and
labeled with anticapsule antibody 3C2 (see Materials and Methods) (top);
immunofluorescence micrographs of the same fields (bottom). Scale bar, 5
m. (B) Negative staining. The indicated strains were grown as indicated for
panel A, mixed with India ink as described in Materials and Methods, and
examined by light microscopy. The average and standard deviation of the
mean capsule thickness for 25 cells is indicated on each panel; this could not be
assessed for the apparently acapsular and highly clumpy double mutant. Scale
bar, 5m. (C) Electronmicroscopy. Each image shows part of the edge of one
representative cell for the strain indicated. gmt1::GMT1 denotes the gmt1mu-
tant chromosomally complemented with the wild-type gene. Scale bar,
250 nm.
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level. However, comparison of strains with different genes in the
same site as their sole GMT sequences suggests otherwise. For
example, expressing GMT2 from the GMT1 locus (strain 5)
yielded consistently smaller capsules than when the endogenous
gene was at that site (strain 3): even expressed at levels similar to
those expected for GMT1, GMT2 did not functionally replace it.
The capsule thickness of each strain (Fig. 8B) generally corre-
lated with total expression of GMT sequences (Fig. 8C), and the
two strains with the lowest GMT expression (and least capsule)
showed cell and colonymorphology consistent with clumpy acap-
sular cells (Fig. 8B and D, strains 4 and 6). To our surprise, how-
ever, the growth of the various strains on rich medium (Fig. 8D)
did not similarly correlate with GMT expression under those
growth conditions (see Fig. S1 in the supplemental material, top
panel). In particular, colonies of strain 5, where GMT2 was ex-
pressed from a nonnative locus, grew slowly (note the small col-
ony size in Fig. 8D) despite robust GMT2 expression in this me-
dium (see Fig. S1 in the supplemental material, top panel); it may
be that this level of GMT2 expression is toxic to the cells (see
Discussion). Furthermore, both of the swapped strains (4 and 5)
were highly sensitive to SDS stress, resembling the double mutant
in rich medium (see Fig. S1 in the supplemental material, bottom
panel). This was the case even though GMT1 expression from
strain 4 was close to GMT2 expression in strain 2 and GMT2
expression in strain 5 exceeded GMT1 expression in strain 3 (see
Fig. S1 in the supplemental material, top panel). These observa-
tions held in multiple independent transformants.
The results of our gene swapping study suggested that factors
beyond gene expression influence Gmt function: despite similar
activity in vitro in an exogenous system, these proteins do not
appear to function identically in vivo even when expressed from
FIG 7 GMT gene expression in wild-type cells under capsule induction con-
ditions. Wild-type KN99 cells were grown under capsule-inducing condi-
tions, and RNA-Seq analysis was performed at 0, 1.5, 3, 8, and 24 h. The
expression values plotted (median	 standard deviation)were calculated from
three separate experiments, each including RNA prepared from three biolog-
ical replicate cultures.
FIG 8 Genomic location does not explain the functional differences betweenGMT1 andGMT2. (A) Schematic representation of theGMT strain variants listed
at left, indicating the coding sequence present at each locus (colored boxes): orange, GMT1; green, GMT2; dark gray, Geneticin resistance marker (G418)
replacing GMT1 (gmt1::G418); light gray, nourseothricin resistance marker (NAT) replacing GMT2 (gmt2::NAT). Promoter and terminator sequences of each
locus (colored lines) were not altered. Strains: 1, wild type; 2, gmt1mutant; 3, gmt2mutant; 4 and 5, new “swapped” strains; 6, gmt1 gmt2 doublemutant. (B) The
capsule thickness of each strain under capsule-inducing conditions was examined with India ink as described in Materials and Methods. Scale bar, 5 m. (C)
GMT expression levels under capsule-inducing conditions determined by RT-PCR, plotted relative to ACT1. (D) Growth on rich medium. Aliquots (5 l) of a
stock cell suspension (2 106 cells/ml) and three 10-fold serial dilutions were spotted on YPD plates and grown for 1 day at 30°C.
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the same locus at similar levels. One possible explanation is that
the proteins are differentially localized. Because both Gmt1 and
Gmt2 complement the loss of S. cerevisiae Vrg4p (39), which is
known to be a Golgi protein (13), we had assumed them to be
similarly localized. However, there is precedent for subcompart-
mentalization of Golgi functions (52) and for association of nu-
cleotide sugar transporters with specific glycosyltransferases (53).
To examine the localization of the Gmt1 andGmt2 proteins by
immunofluorescence microscopy, we modified the chromosomal
copies of GMT1 and GMT2 to encode C-terminally epitope-
tagged proteins (Gmt1-HA and Gmt2-FLAG); we know from our
previous studies that C-terminally modified GMTs are still func-
tional (39). When we probed the resulting doubly tagged strain
with both anti-HA and anti-FLAG antibodies, we observed stain-
ing of large puncta in a perinuclear distribution, consistent with
Golgi localization (4, 13). Neither protein colocalized with BiP, a
marker of the endoplasmic reticulum (not shown). To improve
resolution, we usedAxioVision 4.8 software (Carl Zeiss) for image
deconvolution. Images processed by an inverse filter algorithm
(Fig. 9, first row) showed that the two Gmt proteins generally
colocalized, although occasional areas where only one was stained
were also detectable (Fig. 9 and data not shown). Application of a
fast iterative algorithm resulted in sharper images but with lower
total signal intensity (Fig. 9, second row, and data not shown). In
such images, we could clearly appreciate the membrane localiza-
tion of the twoGmt proteins, as well as regions where they did not
completely colocalize (examples indicated by arrowheads); inter-
estingly, the latter consistently gave the impression that regions of
Gmt1 staining surrounded those of Gmt2 localization (Fig. 9 and
data not shown). This result held even when the secondary anti-
body fluorophores were swapped to rule out potential artifacts
due to staining or fluorophore properties (Fig. 9, third and fourth
rows).
DISCUSSION
C. neoformans has two functional GDP-mannose transporters,
which show the same biochemical activity in vitro (39). Surpris-
ingly, cells lacking both of these proteins grow well, although they
are somewhat compromised in growth under stress (Fig. 1 and 2).
This contrasts with findings in S. cerevisiae and most other fungi
that have been tested, where GDP-mannose transport is essential
(12, 21, 23, 24). A. fumigatus is notably also viable without its
single GDP-mannose transporter, but the mutant is severely de-
fective in growth and cannot spread or sporulate (22). There are
several possible explanations for the robustness of C. neoformans
gmt1 gmt2 cells. One is that Golgi glycan synthetic reactions in-
volving mannose, such as the extension of protein-linked glycans,
are not needed for cryptococcal viability or virulence. This is con-
FIG 9 Gmt proteins are located in theGolgi complex. Chromosomally expressedGmt1-HA andGmt2-Flag were immunolocalized and imaged as detailed in the
text. Shown are single-channel andmerged images of signal derived from staining with DAPI (4=,6-diamidino-2-phenylindole) (nucleus) and with antibodies to
the two tags as indicated. Arrowheads indicate examples of regions where Gmt1 andGmt2 do not colocalize; broken white lines indicate the cell edge as observed
under bright-field microscopy. Scale bar, 5 m.
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sistent with the findings of Park et al. in studies of C. neoformans
mutants unable to initiate Golgi-1,6-mannose branching (3). In
this regard, it is also notable that cryptococcal N-glycan extension
is more limited than that of S. cerevisiae or C. albicans (2); this is
also the case forA. fumigatus (54). Another possibility is that other
C. neoformans nucleotide sugar transporters that are localized to
theGolgi complex have sufficiently relaxed specificity to transport
some amount of GDP-mannose. Our finding that protein N-gly-
cans in gmt1 gmt2 cells are apparently devoid of the terminal
-1,6-mannose modification that is normally acquired in the
Golgi complex (Fig. 4A) argues against this, but additional glycan
analysis will be required to resolve this question.
Gmt1 andGmt2 behave similarly in terms of in vitro assays and
complementation of an S. cerevisiae mutant defective in GDP-
mannose transport (39). However, the gmt1 and gmt2 single mu-
tants have distinct phenotypes, with greater or lesser differences
from thewild type depending on the biological process queried. In
some cases, both single mutants resemble the wild type, as with
cell wall integrity (Fig. 2) or virulence (Fig. 3 and data not shown).
In others, the two single mutants exhibit modest differences; an
example of this is protein glycosylation, where a size shift suggest-
ing reduced terminal glycan modification is seen in a subset of
gmt1 polypeptides but not seen in gmt2 polypeptides (Fig. 4B and
data not shown). There are also striking differences between the
two mutants. For example, gmt1 cells show significant reduction
in capsule thickness and fiber density compared to the wild type.
These capsule defects are reflected in colony appearance and cell
clumping in culture and cannot be overcome by capsule-inducing
conditions. In contrast, capsule is normal in gmt2 cells by all of
these tests. Distinct phenotypes have also been observed in A.
nidulans mutants lacking one of a pair of GDP-mannose trans-
porter genes (25, 26), although a doublemutant in that systemhas
not been reported.
We initially postulated that the activities of Gmt1 and Gmt2
are simply redundant, which would be consistent with the more
extreme defects of cells lacking both transporters. In this case, the
different single mutant phenotypes could reflect differential ex-
pression of the two proteins, as has been suggested for A. nidulans
(25, 26). In line with this idea, our RNA-Seq results indicate that
GMT1mRNA expression is severalfold higher than that of GMT2
in rich medium and rises to 1 order of magnitude higher under
capsule-inducing conditions. Immunostaining and immunoblot-
ting studies (not shown) also suggested that Gmt1 is also more
abundant at the protein level, although in those experiments the
two proteins bore different epitope tags, so the comparison is not
definitive. In this model, the lack of the more abundant protein,
Gmt1, would be expected to havemore dramatic consequences, as
we do observe for several phenotypes that we tested. The differing
effects on various biosynthetic processes seen in each mutant
might then reflect cellular prioritization of glycan synthetic path-
ways in the context of enzymatic competition for use of a limited
resource (Golgi complex-localizedGDP-mannose). Alternatively,
the differing extents of perturbation of various cellular processes
could parallel the overall demand forGDP-mannose: capsule pro-
duction under inducing conditions, for example, likely requires
more mannose than does N-glycan outer chain modification.
Although amodel of completely redundant activities is consis-
tent with many of our results, it raises the question of why C.
neoformans and its sister species Cryptococcus gattii, which di-
verged over 45million years ago, have eachmaintained two copies
of this transporter. Furthermore, simple movement of each gene
to the genomic location of the other did not yield the phenotypes
that would be expected from the resulting modulation of RNA
expression levels if the gene products behaved identically (Fig. 8);
overexpression of GMT2 also did not complement the defects in
gmt1 mutant cells (data not shown). These studies suggest an al-
ternative model, whereby the two transporters in fact play differ-
ent roles, although they can compensate for each other to a certain
extent in the setting of single mutants. This hypothesis is sup-
ported by the distinct expression patterns of the two genes across
multiple growth conditions (39), including opposite responses to
capsule-inducing conditions (Fig. 7). The higher substrate affinity
of Gmt2, which has a Km for GDP-mannose that is twice that of
Gmt1 (39), also suggests distinct functions of the two proteins, as
does our observation thatwhenGMT2 is expressed atGMT1 levels
(Fig. 8, strain 5), it has adverse effects on cell growth (Fig. 8D and
Fig. S1 in the supplemental material); potentially Gmt2 directs
substrate to less productive biosynthetic pathways. Interestingly,
the two Gmt proteins in A. nidulans also demonstrate different
expression patterns that suggest distinct roles in development
(26).
Our imaging studies (Fig. 9) hint that although the two trans-
porters largely colocalize, theymay also occur in distinct locations
within the secretory pathway. This could in turn enable associa-
tion with distinct glycosyltransferases or synthetic complexes that
mediate specific cellular functions andmay also influence protein
stability. Reports from studies of mammals, yeasts, insects, and
plants suggest that subcompartmentalization contributes to effi-
cient organization of glycan synthesis in eukaryotes (52, 55, 56).
Defining such compartments in C. neoformans, however, will re-
quire resolution beyond those of the methods that we have em-
ployed (standard immunofluorescence with deconvolution soft-
ware) because of the limits imposed by the size of this yeast and its
organelle structure; newer microscopy approaches, such as sto-
chastic optical reconstructionmicroscopy (STORM) (57), may be
required for these studies.
We did consider the possibility that Gmt1 and Gmt2 interact
with each other. The Vrg4 protein in S. cerevisiae dimerizes, which
is important for its GDP-Man transport activity (58, 59), and the
LPG2GDP-mannose transporter of Leishmania functions as a ho-
mohexamer (60). Preliminary studies (not shown) did not reveal
such interactions. Furthermore, the differing regulation and rela-
tive abundance of the two transcripts and the similar phenotypes
of wild type and gmt2 cells argue against this model. Nonetheless,
we cannot strictly rule out this possibility.
It is notable that gmt1 cells do not show a significant defect
in virulence, despite reduced capsule and several underglyco-
sylated proteins. It appears that the mutant yeast cells, which
do maintain some capsule, are able to sufficiently balance gly-
can synthetic processes in vivo to compensate for reducedman-
nose utilization. The double mutant strain, in contrast, clearly
demonstrates the critical role of mannose glycosylation in C.
neoformans. This strain is sensitive to stress and temperature, has
incompleteN-glycans, is essentially acapsular, and is avirulent in a
mouse model of infection. The lack of virulence of the double
mutant, coupled with the fact that humans and other mammalian
hosts of C. neoformans do not express GDP-mannose transport-
ers, suggests these proteins as potential targets for antifungal che-
motherapy.
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